Skip to main content
. 2018 Aug 29;38(4):BSR20180547. doi: 10.1042/BSR20180547

Figure 2. MiR-216a increases cisplatin resistance in ovarian cancer cells.

Figure 2

(A) The expression levels of miR-216a in SKOV3 and cisplatin-resistant SKOV3 CR cells was determined by real-time PCR. U6 was used as an input control. (B) The expression levels of miR-216a in SKOV3 cells treated with cisplatin (4 μg/ml) for different times was determined by real-time PCR. U6 was used as an input control. (C) Cell viability of SKOV3, SKOV3 CR cells transfected with or without miR-216a inhibitor treated with different concentrations of cisplatin was determined by MTT assay. (D) Cell viability of SKOV3 CR, SKOV3 cells transfected with or without miR-216a mimics treated with different concentrations of cisplatin was determined by MTT assay. (E) The proliferation of OVCA433 CR cells transfected with or without miR-216a inhibitor and treated with cisplatin (4 μg/ml) was determined by soft agar colony formation assay. Scale bars: 500 μm. (F) The statistical results of soft agar colony formation assay. Data are shown as mean ± S.D. **P<0.01; ***P<0.001; (Student’s ttest in (F,H) and others ANOVA test).